Phase I Study of Safety and Immunogenicity of ADU-623
Status:
Completed
Trial end date:
2018-08-15
Target enrollment:
Participant gender:
Summary
This is a study for patients with brain tumors called astrocytic tumors. The study will
enroll patients who have received standard treatment. The study will test a vaccine called
ADU-623. ADU-623 has not been tested in humans before, so the goal of this study is to see if
ADU-623 can be given safely to brain cancer patients and what is the better dose to give
patients among the three doses that planned to be tested. This study will also evaluate the
length of time before patients' cancer worsens and if ADU-623 helps patients to live longer.
The study will also measure the body's immune system response to ADU-623.